Studies have shown that high CXCL10 concentrations in advanced serous ovarian cancer patients correlated with better survival through attraction and infiltration of T cells [30], thus encouraging the use of combinatorial treatments. This evidence concerns the gene CXCL10 and ovarian serous adenocarcinoma.